{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["32(2)"],"submitter":["Wiegand RE"],"pubmed_abstract":["We evaluated effectiveness of respiratory syncytial virus (RSV) vaccines against RSV-associated thromboembolic events among community-dwelling Medicare fee-for-service beneficiaries >65 years of age in the United States enrolled during October 1, 2023-March 30, 2024. RSV vaccines protected against RSV-associated thromboembolic events (effectiveness 79% [95% CI 74%-83%]) in the same season as vaccine receipt."],"journal":["Emerging infectious diseases"],"pagination":["246-249"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12928231"],"repository":["biostudies-literature"],"pubmed_title":["Effectiveness of RSV Vaccines against RSV-Associated Thromboembolic Events."],"pmcid":["PMC12928231"],"pubmed_authors":["Sung HM","Kautz A","Link-Gelles R","Mak J","Chillarige Y","Wiegand RE","Najdowski M","Lai Y","Payne AB","Zhang Y","Chen Y","Chavez A","Jiao Y"],"additional_accession":[]},"is_claimable":false,"name":"Effectiveness of RSV Vaccines against RSV-Associated Thromboembolic Events.","description":"We evaluated effectiveness of respiratory syncytial virus (RSV) vaccines against RSV-associated thromboembolic events among community-dwelling Medicare fee-for-service beneficiaries >65 years of age in the United States enrolled during October 1, 2023-March 30, 2024. RSV vaccines protected against RSV-associated thromboembolic events (effectiveness 79% [95% CI 74%-83%]) in the same season as vaccine receipt.","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-16T17:45:06.793Z","creation":"2026-07-09T11:09:41.124Z"},"accession":"S-EPMC12928231","cross_references":{"pubmed":["41714840"],"doi":["10.3201/eid3202.251520"]}}